Visual impairment certification secondary to ARMD in Leeds, 2005–2010: is the incidence falling?
Open accessAbstract
Aim The aim of this study was to evaluate trends in visual impairment certification due to age-related macular degeneration (ARMD) in the Leeds metropolitan area between 2005 and 2010.Methods In this retrospective study, the primary causes of visual impairment certification in the Leeds metropolitan area between 2005 and 2010 were reviewed. ARMD was considered to be the cause of certification when recorded as the primary factor contributing to visual impairment in one or both eyes. The incidence of visual impairment certification due to ARMD was calculated using population estimates from the Office of National Statistics.Results ARMD was the primary cause of visual impairment certification in all study years, accounting for 58.7 and 50.8% of certifications in 2005 and 2010, respectively. For the same period, the incidence of certification due to ARMD fell from 364 to 248 per million population per year. This was largely the result of a fall in the incidence of visual impairment certification due to neovascular ARMD from 225 to 137 per million population per year, beginning in 2008 after the introduction of a local commissioning policy on the use of intra-vitreal ranibizumab.Conclusion The incidence of visual impairment certification due to ARMD in the Leeds metropolitan area appears to be falling. This is largely the result of a decrease in certification secondary to neovascular ARMD. This represents a change in the previously described trend for ARMD visual impairment certification.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Anti-VEGF therapies have substantially reduced severe visual loss and disability from neovascular age-related macular degeneration at the population level in several developed economies.
“The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant impact on the reduction of the visual loss due to neovascular age-related macular degeneration (n-AMD).”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [3]
The Abstract and Discussion report that certification for visual impairment due to neovascular ARMD fell in Leeds after ranibizumab was introduced. But the Discussion explicitly says the study cannot determine whether treatment caused the decrease, and the Conclusion calls for research on its relevance to larger populations. The paper therefore does not establish a treatment-driven reduction across several developed economies. (LLM, conf=0.88)
Experimental — accuracy not yet measuredThe overall effectiveness of anti-VEGF therapies in n-AMD is unquestionable.
“The overall effectiveness of anti-VEGF therapies in n-AMD is unquestionable.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [3]
The Introduction says ranibizumab stabilises visual acuity in the majority of neovascular ARMD cases. However, the paper addresses one anti-VEGF treatment rather than therapies overall, and the Discussion says it cannot determine whether the decline in certifications was a direct consequence of its introduction. The claim’s unqualified certainty goes beyond the source. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bird, A. C., Bressler, N. M., Bressler, S. B., Chisholm, I. H., Coscas, G., Davis, M. D., de Jong, P. T. V. M., Klaver, C. C. W., Klein, B. E. K., Klein, R., et al. (1995) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80092-x · Cited by 1,926 · see citing works
Clinical Ophthalmology: A Systematic Approach
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080100041028 · Cited by 852 · see citing works
Mitchell, P. L. R., Jf, K., Lanzetta, P., Holz, F. G., Prünte, C. F., Schmidt-Erfurth, U. M., Tano, Y., & Wolf, S. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.159160 · Cited by 297 · see citing works
Rosenfeld, P. J., Shapiro, H., Tuomi, L., Webster, M. K., Elledge, J. A., & Blodi, B. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.07.011 · Cited by 253 · see citing works
Leading causes of certification for blindness and partial sight in England & Wales
Bunce, C., & Wormald, R. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-58 · Cited by 246 · see citing works
Owen, C. G. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.3.312 · Cited by 211 · see citing works
Is the incidence of registrable age-related macular degeneration increasing?
Evans, J., & Wormald, R. (1996) · British Journal of Ophthalmology · doi:10.1136/bjo.80.1.9 · Cited by 197 · see citing works
Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008
Bunce, C., Xing, W., & Wormald, R. (2010) · Eye · doi:10.1038/eye.2010.122 · Cited by 185 · see citing works
The incidence and causes of blindness in England and Wales, 1948-1962
Sorsby, A. (1972) · Cited by 95 · see citing works
Unrecognised and unregistered visual impairment.
Robinson, R., Deutsch, J., JONES, H., Youngson‐Reilly, S., Hamlin, D., Dhurjon, L., & Fielder, A. R. (1994) · British Journal of Ophthalmology · doi:10.1136/bjo.78.10.736 · Cited by 82 · see citing works
Incidence of blindness due to diabetic eye disease in Fife 1990-9
Cormack, T. G. M. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.3.354 · Cited by 32 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355 · see citing works
Finger, R. P., Daïen, V., Eldem, B. M., Talks, J. S., Korobelnik, J., Mitchell, P. L. R., Sakamoto, T., Wong, T. Y., Pantiri, K., & Carrasco, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01554-2 · Cited by 141 · see citing works
Khanani, A. M., Guymer, R. H., Basu, K., Boston, H., Heier, J. S., Korobelnik, J., Kotecha, A., Lin, H., Silverman, D. G., Swaminathan, B., et al. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100076 · Cited by 86 · see citing works
Using magnetic resonance imaging to assess visual deficits: a review
Brown, H. D. H., Woodall, R., Kitching, R. E., Baseler, H. A., & Morland, A. B. (2016) · Ophthalmic and Physiological Optics · doi:10.1111/opo.12293 · Cited by 80 · see citing works
Gale, R. P., Mahmood, S., Devonport, H., Patel, P. J., Ross, A. H., Walters, G., Downey, L., Elsherbiny, S., Freeman, M., Berry, S., et al. (2019) · Eye · doi:10.1038/s41433-018-0300-3 · Cited by 67 · see citing works
Souied, E. H., Dugel, P. U., Ferreira, A., Hashmonay, R., Lu, J., & Kelly, S. P. (2016) · Ophthalmic Epidemiology · doi:10.3109/09286586.2015.1090004 · Cited by 66 · see citing works
Kelly, S. P., Michelotti, M. M., Abugreen, S., Morarji, J., Myerscough, D., Haughton, A., Nixon, N., Mason, B., Sioras, E., & Boddie, T. (2014) · Clinical ophthalmology · doi:10.2147/opth.s59982 · Cited by 38 · see citing works
UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV
Johnston, R. L., Lee, A., Buckle, M., Antcliff, R. J., Bailey, C., McKibbin, M., Chakravarthy, U., & Tufail, A. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.07.037 · Cited by 36 · see citing works
Self-citationRees, A., Zekite, A., Bunce, C., & Patel, P. J. (2014) · Eye · doi:10.1038/eye.2014.103 · Cited by 34 · see citing works
Talks, J. S., Daïen, V., Finger, R. P., Eldem, B. M., Sakamoto, T., Cardillo, J. A., Mitchell, P., Wong, T. Y., & Korobelnik, J. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.02.008 · Cited by 30 · see citing works
Keenan, T. D. L., Kelly, S. P., Sallam, A., Mohamed, Q., Tufail, A., & Johnston, R. L. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303233 · Cited by 29 · see citing works
Shatz-Binder, W., Hass, P. E., Peer, N., Paluch, M. T., Blanchette, C., Han, G., Sandoval, W. N., Morando, A., Loyet, K. M., Bantseev, V., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218613 · Cited by 28 · see citing works
Boyce, T., Leamon, S. M., Slade, J., Simkiss, P., Rughani, S., & Ghanchi, F. D. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004319 · Cited by 26 · see citing works
Buckle, M., Lee, A., Mohamed, Q. A., Fletcher, E. C., Sallam, A. B., Healy, R., STRATTON, I. M., Tufail, A., & Johnston, R. L. (2015) · Eye · doi:10.1038/eye.2014.296 · Cited by 20 · see citing works
What is new in the management of wet age-related macular degeneration?
Sivaprasad, S., & Hykin, P. G. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt004 · Cited by 18 · see citing works
Jeffery, R. C. H., Mukhtar, S. A., Lopez, D. G., Preen, D. B., McAllister, I. L., Mackey, D. A., Morlet, N., Morgan, W. H., & Chen, F. K. (2021) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000415 · Cited by 18 · see citing works
Risk factors of age-related macular degeneration in Argentina
Nano, M. E., Lansingh, V. C., Pighin, M. S., Zarate, N., Nano, H. D., Carter, M. J., Furtado, J. M., Nano, C. C., Vernengo, L. F., Luna, J. D., et al. (2013) · Arquivos Brasileiros de Oftalmologia · doi:10.1590/s0004-27492013000200005 · Cited by 12 · see citing works
Fulcher, C., Hazel, C. A., Pacey, I. E., Ali, H., & Ghanchi, F. D. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119839299 · Cited by 9 · see citing works
Rees, A., Bunce, C., & Patel, P. J. (2013) · Eye · doi:10.1038/eye.2013.82 · Cited by 9 · see citing works
Tschuor, P., Pilly, B., Venugopal, D., & Gale, R. P. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2332-5 · Cited by 5 · see citing works
Savage, N., Claridge, K. G., & Green, J. (2018) · British Journal of Visual Impairment · doi:10.1177/0264619618756471 · Cited by 2 · see citing works
Results of Lucentis use as a routine practice in wet age-related macular degeneration patients
Loskutov, I. A. (2014) · Ophthalmology Reports · doi:10.17816/ov2014147-57 · Cited by 2 · see citing works
Optometric low vision rehabilitation practice in Norway - public health care
Helland, B., & Sundling, V. (2015) · Scandinavian Journal of Optometry and Visual Science · doi:10.5384/sjovs.vol8i2p11-
- Authors
- Rostron, E., & McKibbin, M.
- Affiliations
- St James's University Hospital (GB)
- Corresponding author
- McKibbin, M
- ORCID
- McKibbin, M
- Venue
- Eye
- Published
- 2012-04-13
- Volume
- 26
- Issue
- 7
- Pages
- 933-936
- ISSN
- 0078-5334 (ISSN-L)
- 0950-222X
- 1476-5454
- PMC
- PMC3396163
- OpenAlex
- W1990047859
- Cited by
- 23
- References
- 12
- Citations by year
- 2021: 2 · 2020: 1 · 2019: 4 · 2018: 1 · 2016: 3 · 2015: 3 · 2014: 4 · 2013: 5
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Eye (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Epidemiology › Ophthalmology and Visual Impairment Studies
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Keywords
- age-related macular degeneration, incidence trends, ranibizumab, anti-VEGF therapy, LEED
- MeSH terms
- England, Humans, Macular Degeneration, Retrospective Studies, Vision Disorders, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
